Table 1. Demographics and baseline characteristics for patients with CRVO or BRVO treated with ranibizumab injection or dexamethasone implant who had 12 months of follow-up data.
| Characteristic |
CRVO (n=1369) |
BRVO (n=1818) |
||||
|---|---|---|---|---|---|---|
| Ranibizumab injection | Dexamethasone implant | P-value | Ranibizumab injection | Dexamethasone implant | P-value | |
| (n=1178) | (n=191) | (n=1644) | (n=174) | |||
| Age, mean, years (SD) | 72.8 (11.5) | 68.8 (11.8) | <0.0001 | 73.3 (10.2) | 72.7 (10.5) | 0.525 |
| Female, n (%) | 623 (52.9) | 98 (51.3) | 0.686 | 948 (57.7) | 89 (51.2) | 0.099 |
| Charlson–Deyo Comorbidity Index, mean (SD) | 0.7 (1.3) | 1.0 (1.4) | 0.011 | 0.6 (1.1) | 0.6 (1.0) | 0.924 |
| Payer type, n (%) | ||||||
| Commercial | 382 (32.4) | 83 (43.5) | <0.0001 | 512 (31.1) | 66 (37.9) | 0.113 |
| Medicare | 781 (66.3) | 100 (52.4) | 1116 (67.9) | 108 (62.1) | ||
| Medicaid | 15 (1.3) | 8 (4.2) | 16 (1.0) | 0 (0.0) | ||
| US geographical region, n (%) | ||||||
| Midwest | 177 (15.0) | 19 (9.9) | 0.034 | 290 (17.6) | 31 (17.8) | <0.0001 |
| Northeast | 333 (28.3) | 61 (31.9) | 485 (29.5) | 46 (26.4) | ||
| West | 516 (43.8) | 75 (39.3) | 689 (41.9) | 55 (31.6) | ||
| South | 152 (12.9) | 36 (18.8) | 180 (10.9) | 42 (24.1) | ||
Abbreviations: BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; SD, standard deviation.